Infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, ustekinumab recommended over no tx
Your search for tofacitinib returned 30 results
Researchers compared the risk for serious infections in offspring of mothers with chronic inflammatory diseases who received non-TNFi biologics or tofacitinib during pregnancy vs offspring who were unexposed, but exposed to TNFi in utero.
TNFi recommended over secukinumab, ixekizumab for AS and nonradiographic axial SpA as first biologic
Investigators assessed the risk for herpes zoster and provided recommendations regarding treatment in patients with psoriasis.
The clinical benefits of tofacitinib in combination with methotrexate are sustained over 2 years among patients with rheumatoid arthritis (RA), according to a study published online January 22 in Arthritis & Rheumatology.
A reduction in risk for cardiovascular disease has been reported among patients with rheumatoid arthritis who are receiving concomitant therapy with methotrexate and biologic disease-modifying antirheumatic drugs.
Although the incidence rate of venous thromboembolism was numerically higher in patients treated with tofacitinib vs TNF inhibitors, the risk was not statistically significant.
The researchers concluded their findings indicate that for patients with RA, abatacept reduced the risk for diabetes and “potentially improved insulin sensitivity and glycemic profile.”
The results support combination therapy with intra-articular steroid injections and tofacitinib to achieve clinical and radiographic remission in patients with early rapid radiographic progression RA.
Tofacitinib extended release has comparable clinical efficacy to tofacitinib administered twice daily.